Sign in to continue:

Thursday, April 30th, 2026

Stepan Company 8-K Filing: Corporate Information, Annual Meeting Results, and SEC Compliance (April 2026)

Stepan Company Reports Results of 2026 Annual Meeting of Stockholders

Stepan Company Reports Results of 2026 Annual Meeting of Stockholders

Key Highlights from the 2026 Annual Meeting

  • Date of Meeting: April 28, 2026
  • Total Shares Represented: 19,939,848 (constituting a quorum)
  • Key Proposals Voted:
    1. Election of three directors (to serve until the 2029 annual meeting)
    2. Advisory vote to approve the compensation of named executive officers (“Say-on-Pay”)
    3. Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026

Detailed Voting Results

1. Election of Directors

Shareholders overwhelmingly re-elected three director nominees to serve until the 2029 annual meeting. The voting results for each nominee were as follows:

Name For Against Abstain Broker Non-Votes
Nominee 1 17,931,815 362,065 36,231 1,609,737
Nominee 2 17,887,420 407,321 35,370 1,609,737
Nominee 3 17,919,767 374,681 35,663 1,609,737

All three directors were elected by a large majority, indicating strong shareholder support for the current leadership team.

2. Advisory Vote to Approve Executive Compensation (“Say-on-Pay”)

For Against Abstain Broker Non-Votes
17,000,565 1,233,415 67,131 1,638,736

The executive compensation program received strong support, with over 91% of votes cast in favor, signaling investor confidence in management’s pay practices and alignment with shareholder interests.

3. Ratification of Deloitte & Touche LLP as Independent Auditors

For Against Abstain
18,939,981 57,235 35,631

The appointment of Deloitte & Touche LLP was ratified with an overwhelming majority, reflecting strong shareholder trust in the company’s choice of independent auditors.

Other Important Shareholder Information

  • Company Name: Stepan Company
  • Ticker Symbol: SCL
  • Exchange: New York Stock Exchange (NYSE)
  • State of Incorporation: Delaware
  • Fiscal Year End: December 31

Potential Price Sensitive Information

  • All directors were re-elected by large margins, indicating no shareholder activism or significant opposition that might signal governance concerns or strategic redirection.
  • The advisory vote on executive compensation passed with over 91% support, suggesting broad investor satisfaction with management and potentially reducing the risk of future activist campaigns related to pay policies.
  • The ratification of the auditor was nearly unanimous, with no signs of accounting or auditing controversies that might worry investors.

There are no new proposals, changes in leadership, or controversial matters revealed in this filing that are likely to materially impact the share price in the immediate term. The results indicate stability and continued shareholder support for the company’s current management and strategy.

Additional Administrative Details

  • Central Index Key (CIK): 0000094049
  • Business Address: Edens & Winnetka Road, Northfield, IL 60093
  • Business Phone: 847-446-7500
  • General Counsel and Secretary: Shawn G. Lisle
  • Date Filed: April 30, 2026

Conclusion

This report provides reassurance to investors of Stepan Company’s stable governance and ongoing shareholder alignment. The lack of any meaningful opposition or controversy suggests a steady outlook for the company, which may be viewed positively by the market, though no price-moving surprises or concerns were identified in this filing.


Disclaimer: This article is based on Stepan Company’s official SEC filing for the 2026 annual meeting. The information presented is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Investors should conduct their own due diligence or consult with their financial advisor before making investment decisions.


View STEPAN CO Historical chart here



ESG Inc. Announces Board Resignation in Form 8-K Filing – March 31, 2026

ESG Inc. Files Form 8-K: Director Resignation and Corporate ...

Coya Therapeutics Reports 2025 Financial Results and Advances ALS & FTD Clinical Trials with Strong Cash Position

Coya Therapeutics, Inc. Provides Corporate Update and Fiscal...

   Ad

Join Our Investing Seminar

Limited seats available — Reserve your spot today